Central European Journal of Medicine

, Volume 2, Issue 3, pp 237–270 | Cite as

Probiotics and prebiotics — renaissance of a therapeutic principle

  • Premysl Fric
Review Article

Abstract

Probiotics are nonpathogenic microorganisms mostly of human origin which, when administered in adequate amounts, confer a health benefit on the host and enable to prevent or improve some diseases. Probiotics may be a natural temporary constituent of the resident intestinal microflora, but their concentration is not sufficient for therapeutic purposes. The microbiota, the intestinal epithelium, and the mucosal immune system constitute the gastrointestinal ecosystem. All three components are essential for complete functional and developmental maturity of the system. The viability of intestinal microflora (including probiotic strains) requires the availability of nutritional substrates (prebiotics), i.e. various types of fiber and oligosaccharides. Prebiotics are cleaved by microbial enzymes to numerous substances (short-chain fatty acids, aminoacids, polyamines, growth factors, vitamins and antioxidants) indispensable for metabolic and functional activities of the intestinal mucosa. The principal probiotics in use include lactobacilli, bifidobacteria, some nonpathogenic strains of Escherichia coli, and Saccharomyces boulardii. These microbiota display favourable effects which qualify them for therapeutic use. For this purpose, probiotics have to fulfill a series of requirements verifying their efficacy and safety. Experimental and clinical studies examine the prerequisites for the administration of probiotics in digestive diseases, allergic and atopic affections, as well as in some extraintestinal conditions. Future goals of probiotic application include genomic analysis, controlled postnatal colonisation of the digestive tract, the use of probiotics as carriers of peroral vaccines, and recombinant probiotics with in-situ production and targeted application of therapeutic molecules.

Keywords

Gastrointestinal ecosystem probiotics prebiotics synbiotics microbial interference therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    R.D. Berg: “The indigenous gastrointestinal microflora”, Trends Microbiol., Vol. 4, (1996), pp. 430–435.PubMedGoogle Scholar
  2. [2]
    E.E. Vaughan, F. Schut, H.G. Heilig, E.G. Zoetendal, W.M. de Vosand and A.D. Akkermans: “A molecular view of the intestinal ecosystem”, Cur. Issues Intest. Microbiol., Vol. 1, (2000), pp. 1–12.Google Scholar
  3. [3]
    D. Dai and W.A. Walker: “Protective nutrients and bacterial colonisation in the immature human gut”, Adv. Pediatr., Vol. 46, (1999), pp. 353–382.PubMedGoogle Scholar
  4. [4]
    K.R. Rozee, D. Cooper, K. Lam and J.W. Costerton: “Microbial flora of the mouse ileum mucosa layer and epithelial surface”, Appl. Environ. Microbiol., Vol. 43, (1982), pp. 1451–1463.PubMedGoogle Scholar
  5. [5]
    A. Lee: Neglected niches: “The microbial etiology of the gastrointestinal tract”, In K.C. Marshal (Ed.): Advances in Microbial Ecology, Plenum Press, New York, 1984, pp. 115–162.Google Scholar
  6. [6]
    A. Swidsinski, A. Ladhoff, A. Pernthaler, S. Swidsinski, V. Loening-Baucke, M. Ortner, J. Weber, U. Hoffmann, S. Schreiber, M. Dietel and H. Lochs: “Mucosal flora in inflammatory bowel disease”, Gastroenterology, Vol.122, (2002), pp. 44–54.PubMedGoogle Scholar
  7. [7]
    H. Cheng and C.P. Leblond: “Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine Parts I–V”, Am. J. Anat., Vol. 141 (1974), pp. 461–562.PubMedGoogle Scholar
  8. [8]
    P.G. Falk, L.V. Hooper, T. Midtvedt and J.I. Gordon: “Creating and maintaining the gastrointestinal ecosystem: What we know and need to know from gnotobiology”, Microbiol. Mol. Biol. Rev., Vol. 62, (1998), pp. 1157–1170.PubMedGoogle Scholar
  9. [9]
    M.F. Kagnoff and L. Eckmann: “Epithelial cells as sensors for microbial infection”, J. Clin. Invest., Vol. 100, (1997), pp. 6–10.PubMedGoogle Scholar
  10. [10]
    V.J. Mc Cracken and R.G. Lorenz RG: “The gastrointestinal ecosystem: A precarious alliance among epithelium, immunity and microbiota”, Cellular Microbiology, Vol. 3. (2001), pp. 1–11.Google Scholar
  11. [11]
    J.R. Mc Ghee, M.E. Lamm and W. Strober: “Mucosal immune responses: An overview”, In: P.L. Ogra (ed.): Mucosal Immunology, Academic Press, San Diego, 1999, pp. 485–506.Google Scholar
  12. [12]
    R.L. Owen: “Uptake and transport of intestinal macromolecules and microorganisms by M cells in Peyer’s patches — a personal and historical perspective”, Semin. Immunol., Vol. 111, (1999), pp. 157–163.Google Scholar
  13. [13]
    M.H. Perdue: “Mucosal immunity and inflammation. III. The mucosal antigen barrier: Cross talk with mucosal cytokines”, Am. J. Physiol., Vol. 277, (1999), pp. G1–G5.PubMedGoogle Scholar
  14. [14]
    S.P. James, H. Kiyono: “Gastrointestinal lamina propria T cells”, In P.L. Ogra (Ed.): Mucosal Immunology, Academic Press, San Diego, 1999, pp. 381–396.Google Scholar
  15. [15]
    A. Fasano: “Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin”, Ann. N. Y. Acad. Sci., Vol. 915, (2000), pp. 214–222.PubMedCrossRefGoogle Scholar
  16. [16]
    W. Wang, S. Uzzau, S.E. Goldblum and A. Fasano: “Human zonulin, a potential modulator of intestinal tight junctions”, J. Cell Sci., Vol. 113, (2000), pp. 4435–4440.PubMedGoogle Scholar
  17. [17]
    A. Fasano, A. Not, W. Wang, S. Uzzau, I. Berti, A. Tomassini and S.E. Goldblum: “Zonulin, a newly discovered modulator of intestinal permeability and its expression in coeliac disease”, Lancet, Vol. 355, (2000), pp. 1518–1519.PubMedGoogle Scholar
  18. [18]
    M. Di Pierro, R. Lu, S. Uzzau, W. Wang, K. Margaretten, C. Pazzani and F. Maimone: “Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain”, J. Biol. Chem., Vol. 276, (2001), pp. 19160–19165.PubMedGoogle Scholar
  19. [19]
    G. Reid, M.E. Sanders, H.R. Gaskins, G.R. Gibson, A. Mercenier, R. Rastall, M. Roberfroid, I. Rowland, C. Cherbut and T.R. Klaenhammer: “New scientific paradigms for probiotics and prebiotics”, J. Clin. Gastroenterol., Vol. 37, (2003), pp. 105–118.PubMedGoogle Scholar
  20. [20]
    P. Becquet: “EU assessment of enterococci as feed additives”, Int. J. Food Microbiol., Vol. 88, (2003), pp. 247–254.PubMedGoogle Scholar
  21. [21]
    S.L. Gorbach: “Probiotics and gastrointestinal health”, Am. J. Gastroenterol., Vol. 95, (2000), pp. S2–S4.PubMedGoogle Scholar
  22. [22]
    D. Rachmilewitz, K. Katakura, F. Karmeli, T. Hayashi, C. Reinus, B. Rudensky, S. Akira, K. Takeda, J. Lee, K. Takabayashi and E. Raz: “Toll-like receptor 9 signalling mediates the antiinflammatory effects of probiotics in murine experimental colitis”, Gastroenterology, Vol. 126, (2004), 520–528.PubMedGoogle Scholar
  23. [23]
    R.B. Sartor: Targeting enteric bacteria in treatment of inflammatory bowel diseases: “Why, how and when”, Curr. Opin. Gastroenterol., Vol. 19, (2003), pp. 358–365.PubMedGoogle Scholar
  24. [24]
    A. Bolotin, P. Wincker, S. Mauger, O. Jaillon, K. Malarme, J. Weissenbach, S.D. Ehrlich and A. Sorokin: “The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL 1403”, Genome Res., Vol. 11, (2001), pp. 731–753.PubMedGoogle Scholar
  25. [25]
    M. Kleerebezem, J. Boekhorst, R. Van Kranenburg, D. Molennar, O.P. Kuipers, R. Leer, R. Tarchini, S.A. Peters, H.M. Sandbrink, M.W. Fiers, W. Stiekema, R.M. Lankhorst, P.A. Bron, S.M. HofferM, M.N. Groot, R. Kerkhoven, M. De Vries, B. Ursing, W.M. De Vos and K.J. Siezen: “Complete genome sequence of Lactobacillus plantarum WCFS1”, Proc. Natl. Acad. Sci. USA, Vol. 100, (2003), pp. 1990–1995.PubMedGoogle Scholar
  26. [26]
    M.A. Schell, M. Karmirantzou, B. Snel, D. Vilanova, B. Berger, G. Pessi, M.C. Zwahlen, F. Desiere, P. Bork, M. Delley, E.D. Pridmore and F. Arigoni: “The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract”, Proc. Natl. Acad. Sci. USA, Vol. 99, (2002), pp. 14422–14427.PubMedGoogle Scholar
  27. [27]
    L. Grozdanov, C. Raasch, J. Schulze, U. Sonnenborn, G. Gottschalk, J. Hacker and U. Dobrindt: “Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917”, J. Bacteriol., Vol. 186, (2004), pp. 5432–5441.PubMedGoogle Scholar
  28. [28]
    J. Sun, F. Gunzer, A.M. Westendorf, J. Buer, M. Scharfe, M. Jarek, F. Gossling, H. Blocker and A.P. Zeng: “Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genomic data”, J. Biotechnol., Vol. 117, (2005), pp. 147–161.PubMedGoogle Scholar
  29. [29]
    W.L. Hooper, M.H. Wong, A. Thelin, L. Hansson, P.G. Falk and J.I. Gordon JI: “Molecular analysis of commensal host-microbial relationships in the intestine”, Science, Vol. 291, (2001), pp. 881–884.PubMedGoogle Scholar
  30. [30]
    L. Steidler: “Genetically engineered probiotics”, Best Pract. Res. Clin. Gastroenterol., Vol. 17, (2003), pp. 861–876.PubMedGoogle Scholar
  31. [31]
    L. Steidler and P. Rottiers: “Therapeutic drug delivery by genetically modified Lactococcus lactis”, Ann. N.Y. Acad. Sci., Vol. 1072, (2006), pp. 176–186.PubMedGoogle Scholar
  32. [32]
    P.G. Cano and G. Perdigon: “Probiotics induce resistance to enteropathogens in a re-nourished mouse model”, J. Dairy Res., Vol. 70, (2003), pp. 433–440.PubMedGoogle Scholar
  33. [33]
    J. Boudeau, A.L. Glasser, S. Julien, I.F. Colombel and A. Darfeuille-Michaud: “Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn’s disease”, Aliment. Pharmacol. Ther., Vol. 18, (2003), pp. 45–56.PubMedGoogle Scholar
  34. [34]
    S. Resta-Lenert and K.E. Barrett: “Live probiotics protect intestinal epithelial cells from the effect of invasion with enteroinvasive Escherichia coli (EIEC)”, Gut, Vol. 52, (2003), pp. 988–997.PubMedGoogle Scholar
  35. [35]
    F. Baquero, M.R. Baquero and F. Foreno: Colicins and microcins: “Ecological significance”, In J. Hacker, W. Kruis (eds.): Gut Flora in Symbiosis and Pathogenicity. 3rd Interdisciplinary Symposium A Nissle Gesellschaft, Hagen, 1998, pp. 23–27.Google Scholar
  36. [36]
    K.L. Madsen, A. Cornish, P. Soper, C. Mc Kaigney, H. Jijon, C. Yachimec, J. Doyle, L. Jewell and C. De Simone: “Probiotic bacteria enhance murine and human intestinal epithelial barrier function”, Gastroenterology, Vol. 121, (2001), pp. 580–591.PubMedGoogle Scholar
  37. [37]
    I. Eizaguirre, N.G. Urkia, I. Ansensio-Abzubillaga, P. Zubillaga, C. Vidales, J.M. Garcia-Arenzana and P. Aldazabal: “Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome”, J. Pediatr. Surg., Vol.37, (2002), pp. 699–702.PubMedGoogle Scholar
  38. [38]
    P. Mangell, P. Nejdfors, M. Wang, S. Ahrne, B. Westrom, H. Thorlacius and B. Jeppsson: “Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability”, Dig. Dis. Sci., Vol. 47, (2002), pp. 511–516.PubMedGoogle Scholar
  39. [39]
    D.C. Baumgart and A.U. Dignass: “Intestinal barrier function”, Curr. Opin. Clin. Nutr. Metab. Care, Vol. 5, (2002), pp. 685–694.PubMedGoogle Scholar
  40. [40]
    H. Ichikawa, T. Kuroiwa, A. Inagaki, R. Shineha, T. Nishihira, S. Satomi and T. Sakata: “Probiotic bacteria stimulate gut epithelial cell proliferation in rat”, Dig. Dis. Sci., Vol. 44, (1999), pp. 2119–2123.PubMedGoogle Scholar
  41. [41]
    M. Banasaz, E. Norin, R. Holma, T. Midtvedt: “Increased enterocyte production in gnotobiotic rats mono-associated with Lactobacillus rhamnosus GG”, Appl. Environ. Microbiol., Vol. 68, (2002), pp. 3031–3034.PubMedGoogle Scholar
  42. [42]
    M. Drakes, T. Blanchard and S. Czinn: “Bacterial probiotic modulation of dendritic cells”, Infect. Immun., Vol. 72, (2004), pp. 3299–3309.PubMedGoogle Scholar
  43. [43]
    J.M. Otte and D.K. Podolsky: “Functional modulation of enterocytes by gram-positive and gram-negative microorganisms”, Am. J. Physiol. Gastrointest. Liver Physiol., Vol. 286, (2004), pp. G613–G626.PubMedGoogle Scholar
  44. [44]
    B. Cukrowska, R. Lodinova-Zadnikova, C. Enders, U. Sonneborn, J. Schulze and H. Tlaskalova-Hogenova: “Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli Nissle 1917”, Scand. J. Immunol., Vol. 55, (2002), pp. 204–209.PubMedGoogle Scholar
  45. [45]
    M. Roller, G. Rechkemmer and B. Watzl: “Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats”, J. Nutr., Vol. 134, (2004), pp. 153–156.PubMedGoogle Scholar
  46. [46]
    S. Pathmakanthan, C.K. Li, J. Cowie and C.J. Hawkey: “Lactobacillus plantarum 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon”, J. Gastroenterol. Hepatol., Vol. 19, (2004), pp. 166–173.PubMedGoogle Scholar
  47. [47]
    M.L. Cross: “Immune signalling by orally-delivered probiotic bacteria: Effects on common mucosal immunoresponses and protection at distal mucosal sites”, Int. J. Immunopathol. Pharmacol., Vol. 17, (2004), pp. 127–134.PubMedGoogle Scholar
  48. [48]
    A.P. Bai, Q. Ouyang and W. Zhang: “Probiotics inhibit TNF-alpha-induced interleukin-8 secretion of HT29 cells”, World J. Gastroenterol., Vol. 1, (2004), pp. 455–457.Google Scholar
  49. [49]
    H. Tlaskalova-Hogenova, R. Stepankova, T. Hudcovic, L. Tuckova, B. Cukrowska, R. Lodinova-Zadnikova, H. Kozakova, P. Rossmann, J. Bartova, D. Sokol, D.P. Funda, D. Borovska, Z. Rehakova, J. Sinkora, J. Hofman, P. Drastich and A. Kokesova: “Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases”, Immunol. Lett., Vol. 93, (2004), pp. 97–108.PubMedGoogle Scholar
  50. [50]
    K.M. Chow, Z.C. Liu, S. Prakash and T. Chang: “Free and microencapsulated Lactobacillus and effects of metabolic induction on urea removal”, Artif. Cells Blood Substit. Immobil. Biotechnol., Vol. 31, (2003), pp. 425–434.PubMedCrossRefGoogle Scholar
  51. [51]
    M. De Roos and M.B. Katan: “Effects of probiotics on diarrhea, lipid metabolism and carcinogenesis: A review of papers published between 1988 and 1998”, Am. J. Clin. Nutr., Vol. 71, (2000), pp. 405–411.PubMedGoogle Scholar
  52. [52]
    E.I. Psomas, D.J. Fletouris, E. Litopoulou-Tzanetaki and N. Tzanetaki: “Assimilation of cholesterol by yeast strains isolated from infant feces and Feta cheese”, J. Dairy. Sci., Vol. 86, (2003), pp. 3416–3422.PubMedGoogle Scholar
  53. [53]
    S. Nobaek, M.L. Johansson, G. Molin, S. Ahrne and B. Jeppsson: “Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome”, Am. J. Gastroenterol., Vol. 95, (2000), pp. 1231–1238.PubMedGoogle Scholar
  54. [54]
    M. Kaliomäki and E. Isolauri: “Pandemic of atopic diseases — a lack of microbial exposure in early infancy?”, Curr. Drug Targets Infect. Disord., Vol. 2, (2002), pp. 193–199.Google Scholar
  55. [55]
    W.P. Schmidt: “Model of the epidemic of childhood atopy”, Med. Sci. Monit., Vol. 10, (2004), pp. HY5–9.PubMedGoogle Scholar
  56. [56]
    R. Lodinova-Zadnikova and U. Sonnenborn: “Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants”, Biol. Neonate, Vol. 71, (1997), pp. 224–232.PubMedCrossRefGoogle Scholar
  57. [57]
    E. Isolauri, T. Arvola, Y. Sutas, E. Moilanen and S. Salminen: “Probiotics in management of atopic eczema”, Clin. Exp. Allergy, Vol. 30, (2000), pp. 1605–1610.Google Scholar
  58. [58]
    M. Kaliomäki and E. Isolauri: “Role of intestinal flora in the development of allergy”, Curr. Opin. Allergy Clin. Immunol., Vol. 3, (2003), pp. 15–20.Google Scholar
  59. [59]
    Z. Vancikova, R. Lodinova-Zadnikova, J. Radl and H. Tlaskalova-Hogenova: “The early postnatal development of salivary antibody and immunoglobulin response in children orally colonized with a nonpathogenic, probiotic strain of E. Coli”, Folia Microbiol., Vol. 48, (2003), pp. 281–287.CrossRefGoogle Scholar
  60. [60]
    M. Rinkinen, E. Westermarck, S. Salminen and A.C. Ouwehand: “Absence of host specificity for in vitro adhesion of probiotic lactic acid bacteria to intestinal mucus”, Vet. Microbiol., Vol. 97, (2003), pp. 55–61.PubMedGoogle Scholar
  61. [61]
    R.D. Berg: “Bacterial translocation from the gastrointestinal tract”, Adv. Exp. Med. Biol., Vol. 473 (1999), pp. 11–30.Google Scholar
  62. [62]
    S.J. Langlands, M.J. Hopkins, N. Coleman and J.H. Cummings: “Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel”, Gut, Vol. 53, (2004), pp. 1610–1616.PubMedGoogle Scholar
  63. [63]
    R.A. Rastall: “Bacteria in the gut: Friends and foes and how to alter the balance”, J. Nutr., Vol. 134, (2004), pp. 2022S–2026S.PubMedGoogle Scholar
  64. [64]
    K. Whelan, P.A. Judd, V.R. Preedy and M.A. Taylor: Enteral feeding: “The effect on faecal output, the faecal microflora and SCFA concentrations”, Proc. Nutr. Soc., Vol. 63, (2004), pp. 105–113.PubMedGoogle Scholar
  65. [65]
    T. Hudcovic, R. Stepankova, J. Cebra and H. Tlaskalova-Hogenova: “The role of microflora in the development of intestinal inflammation: Acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice”, Folia Microbiol., Vol. 46, (2001), pp. 565–572.Google Scholar
  66. [66]
    K.L. Madsen, J.S. Doyle, L.D. Jewell, M.M. Tavernini and R.N. Fedorak: “Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice”, Gastroenterology, Vol. 116, (1999), pp. 1107–1114.PubMedGoogle Scholar
  67. [67]
    M. Schultz, U.G. Strauch, H.J. Linde, S. Watzl, F. Obermeier, C. Gottl, N. Dunger, N. Grunwald, J. Scholmerich and H.C. Rath: “Preventive effects of E. coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis”, Clin. Diagn. Lab. Immunol., Vol. 11, (2004), pp. 372–378.PubMedGoogle Scholar
  68. [68]
    A. Altenhoefer, S. Oswald, U. Sonnenborn, C. Enders, J. Schulze, J. Hacker and T.A. Oelschlaeger: “The probiotic Escherichia coli Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens”, FEMS Immunol. Med. Microbiol., Vol. 40, (2004), pp. 223–229.PubMedGoogle Scholar
  69. [69]
    J. Wehkamp, J. Harder, K. Wehkamp, B. Wehkamp-von Meissner, M. Schlee, C. Enders, U. Sonnenborn, S. Nuding, S. Bengmark, K. Fellermann, J.M. Schroder and E.F. Stange: “NF-kappaB and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: A novel effect of a probiotic bacterium”, Infect. Immunol., Vol. 72, (2004), pp. 5750–5758.Google Scholar
  70. [70]
    L.A. Dieleman, M.S. Goerres, A. Arends, D. Sprengers, C. Torrice, F. Hoentjen, W.B. Grenther and R.B. Sartor: “Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment”, Gut, Vol. 52, (2003), pp. 370–376.PubMedGoogle Scholar
  71. [71]
    R.B. Sartor: “Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics and prebiotics”, Gastroenterology, Vol. 126, (2004), pp. 1620–1633.PubMedGoogle Scholar
  72. [72]
    O. Shibolet, F. Karmeli, R. Eliakim, E. Swennen, P. Brigidi, P. Gionchetti, M. Campieri, S. Morgenstern and D. Rachmilewitz: “Variable response to probiotics in two models of experimental colitis in rats”, Inflamm. Bowel Dis., Vol. 8, (2002), pp. 399–406.PubMedGoogle Scholar
  73. [73]
    J. Hirano, T. Yoshida, T. Sugiyama N. Koide, T. Mori and T. Yokochi: “The effect of Lactobacillus rhamnosus on enteropathogenic Escherichia coli infection of human intestinal cells in vitro”, Microbiol. Immunol., Vol. 47, (2003), pp. 405–409.PubMedGoogle Scholar
  74. [74]
    D.R. Mack, S. Michal, S. Wei, L. Mc Dougall and M.A. Hollingsworth: “Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression”, Am. J. Physiol., Vol. 276, (1999), pp. G941–950.PubMedGoogle Scholar
  75. [75]
    C. Pothoulakis, C.P. Kelly, M.A. Joshi, N. Gao, C.J. O’Keane, I. Castagliuolo and J.T. Lamont: “Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum”, Gastroenterology, Vol. 104, (1993), pp. 1108–1115.PubMedGoogle Scholar
  76. [76]
    J.P. Buts, N. De Keysser and L. De Raedemaeker: “Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines”, Pediatr. Res., Vol. 36, (1994), pp. 522–527.PubMedGoogle Scholar
  77. [77]
    J.I. Alak, B.W. Wolf, E.G. Mdurvwa, G.E. Pimentel-Smith, S. Kolavala, H. Abdelrahman, S. Suppiramaniam: “Supplementation of Lactobacillus reuteri or L. acidophilus reduced intestinal shedding of Cryptosporidium parvum oocysts in immunodeficient C57BL/6 mice”, Cell. Mol. Biol., Vol. 45, (1999), pp. 855–863.PubMedGoogle Scholar
  78. [78]
    M. Freitas, E. Tavan, K. Thoreux, C. Cayuela, C. Sapin and G. Trugnan: “Lactobacillus casei DN-114001 and Bacteroides thetaiotaomicron VPI-5482 inhibit rotavirus infection by modulating apical glycosylation pattern of cultured human intestinal HT29-MTX cells”, Gastroenterology, Vol. 124, (2003), pp. A475–476.Google Scholar
  79. [79]
    A. Challa, D.R. Rao, C.B. Chawan and L. Shackelford: “Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic abberant crypt foci in rats”, Carcinogenesis, Vol. 18, (1997), pp. 517–521.PubMedGoogle Scholar
  80. [80]
    B.S. Reddy: “Possible mechanisms by which pro-and prebiotics influence colon carcinogenesis and tumor growth”, J. Nutr., Vol. 129, (1999), pp. S1478–S1482.Google Scholar
  81. [81]
    I. Wollowski, G. Rechkemmer and B.L. Pool-Zobel: “Protective role of probiotics and prebiotics in colon cancer”, Am. J. Clin. Nutr., Vol. 73, (2001), pp. 5451–5455.Google Scholar
  82. [82]
    G. Jan, A.S. Belzacq, D. Haouzi, A. Rouault, D. Metivier, G. Kroemer and C. Brenner: “Propionibacteria induce apoptosis of colorectal carcinoma cells via shortchain fatty acids acting on mitochondria”, Cell Death Differ., Vol. 9, (2002), pp. 179–188.PubMedGoogle Scholar
  83. [83]
    J. Saikali, C. Picard, M. Freitas and P. Holt: “Fermented milks, probiotic cultures and colon cancer”, Nutr. Cancer, Vol. 49, (2004), pp. 14–24.PubMedGoogle Scholar
  84. [84]
    F. Marotta, Y. Naito, E. Minelli, H. Tajiri, J. Borticcelli, C.C. Wu, C.H. Min, P. Hotten and E. Fesce: “Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions”, Hepatogastroenterology, Vol. 50, (2003), pp. 1914–1918.PubMedGoogle Scholar
  85. [85]
    C.K. Hsu, J.W. Liao, Y.C. Chung, C.P. Hsieh and Y.C. Chan: “Xylooligosaccharides and fructooligosaccharides affect the intestinal microbiota and precancerous colonic lesion development in rats”, J. Nutr., Vol. 134 (2004), pp. 1523–1528.PubMedGoogle Scholar
  86. [86]
    M. Roller, A. Pietro Femia, G. Caderni, G. Rechkemmer and B. Watzl: “Intestinal immunity of rats with colon cancer is modulated by oligofructose enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis”, Br. J. Nutr., Vol. 92, (2004), pp. 931–938.PubMedGoogle Scholar
  87. [87]
    J.M. Llovet, R. Bartoli, R. Planas, E. Cabre, M. Jimenez, A. Urban, I. Ojanguren, J. Arnal and M.A. Gassull: “Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis”, Gut, Vol. 35, (1994), pp. 1648–1652.PubMedGoogle Scholar
  88. [88]
    J.M. Llovet, R. Bartoli, F. March, R. Planas, B. Vinado, E. Cabre, J. Arnal, P. Coll, V. Ausina and M.A. Gassull: “Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: Molecular epidemic evidence”, J. Hepatol., Vol. 28, (1998), pp. 307–313.PubMedGoogle Scholar
  89. [89]
    T.M. Bauer, J. Fernandez, M. Navasa, J. Vila and J. Rodes: “Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis”, J. Hepatol., Vol. 36, (2002), pp. 501–506.PubMedGoogle Scholar
  90. [90]
    Z. Li, S. Yang and H. Lin: “Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease”, Hepatology, Vol.37, (2003), pp. 343–350.PubMedGoogle Scholar
  91. [91]
    G. Mangiante, G. Colucci, P. Canepari, C. Bassi, N. Nicoli, A. Casaril, P. Marinello, C. Signoretto and S. Bengmark: “Lactobacillus plantarum reduces infection of pancreatic necrosis in experimental acute pancreatitis”, Dig. Surg., Vol. 18, (2001), pp. 47–50.PubMedGoogle Scholar
  92. [92]
    S. Akyol, M.R. Mas, B. Comert, U. Ateskan, M. Yasar, H. Aydogan, S. Deveci, C. Akay, H. Mas, N. Yener and I.H. Kocar: “The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis”, Pancreas, Vol. 26, (2003), pp. 363–367.PubMedGoogle Scholar
  93. [93]
    K.C. Johnson-Henry, D.J. Mitchell, Y. Avitzur, E. Galindo-Mata, N.L. Jones and P.M. Sherman: “Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice”, Dig. Dis. Sci., Vol. 49, (2004), pp. 1095–1102.PubMedGoogle Scholar
  94. [94]
    R. Endersby, J. Walker and H. Jijon: “Probiotic bacteria alternate pro-inflammatory cytokine secretion and maintain colonic permeability in a murine model of sepsis”, Gastroenterology, Vol. 124, (2003), pp. A–477.Google Scholar
  95. [95]
    F. Guarner, F. Casellas, N. Borruel, M. Antolin, S. Videla, J. Vilaseca and J.R. Malagelada: “Role of microecology in chronic inflammmatory bowel diseases”, Eur. J. Clin. Nutr., Vol. 56 (Suppl 4), (2002), pp. S34–S38.Google Scholar
  96. [96]
    R.N. Fedorak and K. L. Madsen: “Probiotics and the management of inflammatory bowel disease”, Inflamm. Bowel Dis., Vol. 10, (2004), pp. 286–299.PubMedGoogle Scholar
  97. [97]
    R.B. Sartor: “Enteric microflora in IBD: Pathogens or commensals?”, Inflamm. Bowel Dis., Vol. 3, (1997), pp. 230–235.Google Scholar
  98. [98]
    F. Shanahan: “Probiotics and inflammatory bowel disease: Is there a scientific rationale?”, Inflamm. Bowel Dis., Vol. 6, (2000), pp. 107–115.PubMedCrossRefGoogle Scholar
  99. [99]
    P. Fric: “Probiotics in the therapy of idiopathic bowel disease”, Postgrad. Med., Vol. 6, (2004), pp. 123–125.Google Scholar
  100. [100]
    R.B. Sartor: “Probiotic therapy of intestinal inflammation and infections”, Curr. Opin. Gastroenterol., Vol. 21, (2005), pp. 44–50.PubMedGoogle Scholar
  101. [101]
    E. Schütz: “Behandlung von Darmerkrankungen mit Mutaflor”, Fortschr. Med., Vol. 107, (1989), pp. 599–602.PubMedGoogle Scholar
  102. [102]
    K. Plein and J. Hotz: “Therapeutic effect of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea — a pilot study”, Z. Gastroenterol., Vol. 31, (1993), pp. 129–134.PubMedGoogle Scholar
  103. [103]
    M.L. McCann, R.S. Abrams and R.P. Nelson: “Recolonization therapy with nonadhesive Escherichia coli treatment of inflammatory bowel disease”, Ann. N.Y. Acad. Sci., Vol. 730, (1994), pp. 243–245.PubMedGoogle Scholar
  104. [104]
    W. Kruis: “Antibiotics and probiotics in inflammatory bowel disease”, Aliment. Pharmacol. Ther., Vol. 20 (Suppl. 4), (2004), pp. 75–78.PubMedGoogle Scholar
  105. [105]
    W. Kruis, E. Schutz, P. Fric, B. Fixa, G. Judmaier and M. Stolte: “Double blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis”, Aliment. Pharmacol. Ther., Vol. 11, (1997), pp. 853–858.PubMedGoogle Scholar
  106. [106]
    T. Pelech, P. Fric, B. Fixa and O. Komarkova: “Comparison of Mutaflor ® and mesalazine in maintenance therapy of inactive of idiopathic proctocolitis”, Prakt. Lek., Vol. 78, (1998), pp. 556–558.Google Scholar
  107. [107]
    B.J. Rembacken, A.M. Snelling, P.M. Hawkey, D.M. Chalmers and A.T. Axon: “Non-pathhogenic Escherichia coli versus mesalalzine for the treatment of ulcerative colitis: a randomised trial”, Lancet, Vol. 354, (1999), pp. 635–639.PubMedGoogle Scholar
  108. [108]
    W. Kruis, P. Fric and M. Stolte: “Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nisssle 1917 and standard mesalamine”, Gastroenterology, Vol. 120, (2001), pp. A–127.Google Scholar
  109. [109]
    W. Kruis, P. Fric, J. Pokrotnieks, M. Lukas, B. Fixa, M. Kascak, M. A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, C. Wolff and J. Schulze: “Maintaining remission of ulcerative colitis with the probiotic Eschericia coli Nissle 1917 is as effective as with standard mesalazine”, Gut, Vol. 53, (2004), pp. 1617–1623.PubMedGoogle Scholar
  110. [110]
    A. Venturi, P. Gionchetti, F. Rizzello, R. Johansson, E. Zucconi, P. Brigidi, D. Matteuzzi and M. Campieri: “Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis”, Aliment. Pharmacol. Ther., Vol. 13, (1999), pp. 1103–1108.PubMedGoogle Scholar
  111. [111]
    H. Ishikawa, I. Akedo, Y. Umesaki, R. Tanaka, A. Imaoka and T. Otani: “Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis”, J. Am. Coll. Nutr., Vol. 22, (2003), pp. 56–63.PubMedGoogle Scholar
  112. [112]
    M. Guslandi, P. Giollo and P.A. Testoni: “A pilot trial of Saccharomyces boulardii in ulcerative colitis”, Eur. J. Gastroenterol. Hepatol., Vol. 15, (2003), pp. 697–698.PubMedGoogle Scholar
  113. [113]
    A. Tursi, G. Brandimarte, G.M. Giorgetti, G. Forti, M.E. Modeo and A. Gigliobianco: “Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-tomoderate ulcerative colitis”, Med. Sci. Monit., Vol. 10, (2004), pp. 126–131.Google Scholar
  114. [114]
    E. Furrie, S. Macfarlane, A. Kennedy, J.H. Cummings, S.V. Walsh, D.A. O’Neil and G.T. Macfarlane: “Synbiotic therapy (Bifidobacterium longum/Synergy) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial”, Gut, Vol. 54, (2005), pp. 242–249.PubMedGoogle Scholar
  115. [115]
    H.R. Malchow: “Crohn’s disease and Escherichia coli. A novel approach in therapy to maintain remission of colonic Crohn’s disease?”, J. Clin. Gastroenterol., Vol. 25, (1997), pp. 653–658.PubMedGoogle Scholar
  116. [116]
    M. Guslandi, G. Mezzi, M. Sorghi and P.A. Testoni: “Saccharomyces boulardii in maintenance treatment of Crohn’s disease”, Dig. Dis. Sci., Vol. 45, (2000), pp. 1462–1464.PubMedGoogle Scholar
  117. [117]
    M. Campieri, F. Rizzello and A. Venturi: “Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease”, Gastroenterology, Vol. 118, (2000), pp. A–781.Google Scholar
  118. [118]
    P. Gionchetti, F. Rizzello, U. Helwig, A. Venturi, K.M. Lammers, P. Brigidi, B. Vitali, G. Poggioli, M. Miglioli and M. Campieri: “Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial”, Gastroenterology, Vol. 124, (2003), pp. 1202–1209.PubMedGoogle Scholar
  119. [119]
    P. Gionchetti, C. Morselli, F. Rizzello, R. Romagnoli, M. Campieri, G. Poggioli, S. Laureti, F. Ugolini and F. Pierangeli: “Management of pouch dysfunction or pouchitis with an ileoanal pouch”, Best. Pract. Res. Clin. Gastroenterol., Vol. 18, (2004), pp. 993–1006.PubMedGoogle Scholar
  120. [120]
    P. Gionchetti, F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggioli, M. Miglioli and M. Campieri: “Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial”, Gastroenterology, Vol. 119, (2000), pp. 305–309.PubMedGoogle Scholar
  121. [121]
    K.O. Laake, P.D. Line, L. Aabakken, T. Lotveit, A. Bakka, J. Eide, A. Roseth, K. Grzyb, A. Bjorneklett and M. H. Vatn: “Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis”, Scand. J. Gastroenterol., Vol. 38, (2003), pp. 409–414.PubMedGoogle Scholar
  122. [122]
    J. Kuisma, S. Mentula, H. Jarvinen, A. Kahri, M. Saxelin and M. Farkkila: “Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora”, Aliment. Pharmacol. Ther., Vol. 17, (2003), pp. 509–515.PubMedGoogle Scholar
  123. [123]
    J.M. Saavedra, N.A. Bauman, I. Oung, J.A. Perman and R.H. Yolken: “Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus”, Lancet, Vol. 344, (1994), pp. 1046–1049.PubMedGoogle Scholar
  124. [124]
    S. Guandalini, L. Pensabene and M.A. Zikri: “Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: A multicenter European trial”, J. Pediatr. Gastroenterol. Nutr., Vol. 30, (2000), pp. 54–60.PubMedGoogle Scholar
  125. [125]
    H. Costa-Ribeiro, T.C. Ribeiro, A.P. Mattos, S.S. Valois, D.A. Neri, P. Almeida, C.M. Cerqueira, E. Ramos, R.J. Young and J.A. Vanderhoof: “Limitations of probiotic therapy in acute, severe dehydrating diarrhea”, J. Pediatr. Gastroenterol. Nutr., Vol. 36, (2003), pp. 112–115.PubMedGoogle Scholar
  126. [126]
    H. RibeiroJr: “Diarrheal disease in a developing nation”, Am. J. Gastroenterol., Vol. 95 (Suppl. 1), (2000), pp. S14–S15.PubMedGoogle Scholar
  127. [127]
    M. Kaila, E. Isolauri E. Soppi, E. Virtanen, S. Laine and H. Arvilommi: “Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain”, Pediatr. Res., Vol. 32, (1992), pp. 141–144.PubMedGoogle Scholar
  128. [128]
    R. Lodinova-Zadnikova, H. Tlaskalova-Hogenova and U. Sonnenborn: “Local and serum antibody response in full-term and premature infants after artificial colonization of the intestine with E. coli strain Nissle 1917 (Mutaflor ®)”, Pediatr. Allergy Immunol., Vol. 3, (1992), pp. 43–48.Google Scholar
  129. [129]
    L.V. McFarland, C.M. Surawicz, R.N. Greenberg, R. Fekety, G.W. Elmer, K.A. Moyer, S.A. Melcher, K. E. Bowen, J.L. Cox and Z. Noorani: “A randomized placebocontrolled trial of Saccharomyces boulardii in combination wit standard antibiotics for Clostridium difficile disease”, JAMA, Vol. 271, (1994), pp. 1913–1918.PubMedGoogle Scholar
  130. [130]
    C.M. Surawicz, L.V. McFarland, G.W. Elmer and J. Chinn: “Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii”, Am. J. Gastroenterol., Vol. 84, (1989), pp. 1285–1287.PubMedGoogle Scholar
  131. [131]
    S.L. Gorbach, T.W. Chang and G. Goldin: “Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG”, Lancet, Vol. 2, (1987), p. 1519.PubMedGoogle Scholar
  132. [132]
    M. Pochapin: “The effect of probiotics on Clostridium difficile diarrhea”, Am. J. Gastroenterol., Vol. 95, (2000), pp. S11–S13.PubMedGoogle Scholar
  133. [133]
    S. Plummer, M.A. Weawer, J.C. Harris, P. Dee and J. Hunter: “Clostridium difficile pilot study: Effects of probiotic supplementation on the incidence of C. difficile diarrhoea”, Int. Microbiol., Vol. 7, (2004), pp. 59–62.PubMedGoogle Scholar
  134. [134]
    A.L. D’souza, C. Rajkumar, J. Cooke and C.J. Bulpitt: “Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis”, Brit. Med. J., Vol. 324, (2002), p. 1361.PubMedGoogle Scholar
  135. [135]
    J.A. Vanderhoof, D.B. Whitney, D.L. Antonson, T.L. Hanner, J.V. Lupo and R.J. Young: “Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children”, J. Pediatr., Vol. 135, (1999), pp. 564–568.PubMedGoogle Scholar
  136. [136]
    T. Arvola, K. Laiho, S. Torkkeli, H. Mykkanen, S. Salminen, L. Maunula and E. Isolauri: “Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections”, Pediatrics, Vol. 104, (1999), p. e64.PubMedGoogle Scholar
  137. [137]
    H. Kollaritsch, H. Holst, P. Grobara and G. Wiedermann: “Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study”, Fortschr. Med., Vol. 111, (1993), pp. 152–156.PubMedGoogle Scholar
  138. [138]
    E. Hilton, P. Kolakowski, C. Singer and M. Smith: “Efficacy of Lactobacillus GG as a diarrheal preventive in travelers”, J. Travel. Med., Vol. 4, (1997), pp. 41–43.PubMedGoogle Scholar
  139. [139]
    A. Tromm, U. Niewerth, M. Khoury, E. Baestline, G. Wilhelms, J. Schulze and M. Stolte: “The probiotic E. coli Nissle 1917 for the treatment of collagenous colitis: First results of an open-label trial”, Z. Gastroenterol., Vol. 42, (2004), pp. 365–369.PubMedGoogle Scholar
  140. [140]
    A. Balsari, A. Ceccarelli and F. Dubini: “The faecal bacterial population in the irritable bowel syndrome”, Microbiologica, Vol. 5, (1982), pp. 185–194.PubMedGoogle Scholar
  141. [141]
    A. Swidsinski, M. Khilkin and M. Ortner: “Alteration of bacterial concentration in colonic biopsies from patients with irritable bowel syndrome (IBS)”, Gastroenterology, Vol. 115, (1999), pp. A–1.Google Scholar
  142. [142]
    T.S. King, M. Elia and J.O. Hunter: “Abnormal colonic fermentation in irritable bowel syndrome”, Lancet, Vol. 352, (1998), pp. 1187–1189.PubMedGoogle Scholar
  143. [143]
    G.M. Halpern, T. Prindville, M. Blankenburg, T. Hsia and M.E. Gershwin: “Treatment of irritable bowel syndrome with Lacteol forte: A randomized, double-blind, cross-over trial”, Am. J. Gastroenterol., Vol. 91, (1996), pp. 1579–1585.PubMedGoogle Scholar
  144. [144]
    M.A. O’sullivan and C.A. O’Morain CA: “Bacterial supplementation in the irritable bowel syndrome: A randomized, double-blind, placebo-controlled crossover study”, Digest. Liver. Dis., Vol. 32, (2000), pp. 294–301.Google Scholar
  145. [145]
    H.J. Kim, M. Camilleri, S. Mc Kinzie, M.B. Lempke, D.D. Burton, G.M. Thomforde and A.R. Zinsmeister: “A randomized controlled trial of a probiotic, VSL 3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome”, Aliment. Pharmacol. Ther., Vol. 17, (2003), pp. 895–904.PubMedGoogle Scholar
  146. [146]
    A. Saggioro: “Probiotics in the treatment of irritable bowel syndrome”, J. Clin. Gastroenterol., Vol. 38, (2004), pp. S104–106.PubMedGoogle Scholar
  147. [147]
    M. Möllenbrink and E. Bruckschen: “Treatment of chronic constipation with physiological E. coli bacteria. Results of a clinical trial on the efficacy and compatibility of microbiological therapy with the E. coli strain Nissle 1917 (Mutaflor ®)”, Med. Klin., Vol. 89, (1994), pp. 587–593.Google Scholar
  148. [148]
    E. Bruckschen and H. Horosiewicz: “Chronische Obstipation. Vergleich von mikrobiologischer Therapie und Laktulose”, Münch. Med. Wschr., Vol. 16, (1994), pp. 241–245.Google Scholar
  149. [149]
    C. Koebnick, I. Wagner, P. Leitzmann, U. Stern and H.J. Zunft: “Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation”, Canad. J. Gastroenterol., Vol. 17 (2003), pp. 655–659.Google Scholar
  150. [150]
    S.M. Faber: “Comparison of probiotics and antibiotics to probiotics alone in treatment of diarrhea predominant IBS (D-IBS), alternating (A-IBS) and constipation (C-IBS) patients”, Gastroenterology, Vol. 118, (2000), pp. A687–688.CrossRefGoogle Scholar
  151. [151]
    P. Fric and M. Zavoral: “The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon”, Eur. J. Gastroenterol. Hepatol., Vol. 15, (2003), pp. 313–315.PubMedGoogle Scholar
  152. [152]
    T.M. Bauer, B. Steinbruckner, F.E. Brinkman, A.K. Ditzen, H. Schwacha, J.J. Aponte, K. Pelz, M. Kist and H.E. Blum: “Small intestinal bacterial overgrowth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis”, Am. J. Gastroenterol., Vol. 96, (2001), pp. 2962–2967.PubMedGoogle Scholar
  153. [153]
    T.M. Bauer, H. Schwacha, B. Steinbruckner, F.E. Brinkmann, A.K. Ditzen, J.J. Aponte, K. Pelz, D. Berger, M. Kist and H.E. Blum: “Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia”, Am. J. Gastroenterol., Vol. 97, (2002), pp. 2364–2370.PubMedGoogle Scholar
  154. [154]
    I. Cirera, T.M. Bauer, M. Navasa, J. Vila, L. Grande, P. Taura, J.J. Fuster, J.C. Garcia-Valdecasas, A. Lacy, M.J. Suarez, A. Rimola and J. Rodes: “Bacterial translocation of enteric organisms in patients with cirrhosis”, J. Hepatol., Vol.34, (2001), pp. 32–37.PubMedGoogle Scholar
  155. [155]
    S. Pascual, J. Such, A. Esteban, P. Zapater, J.A. Casellas, J.R. Aparicio, E. Girona, A. Gutierrez, F. Carnices, J.M. Palazon, J. Sola-Vera and M. Perez-Mateo: “Intestinal permeability is increased in patients with advanced cirrhosis”, Hepatogastroenterology, Vol. 50, (2003), pp. 1482–1486.PubMedGoogle Scholar
  156. [156]
    Di Leo, C. Venturi, A. Baragiotta, D. Martines and A. Floreani: “Gastroduodenal and intestinal permeability in primary biliary cirrhosis”, Eur. J. Gastroenterol. Hepatol., Vol. 15, (2003), pp. 967–973.PubMedGoogle Scholar
  157. [157]
    B. Campillo, P. Pernet, P.N. Bories, J.P. Richardet, M. Devanlay and C. Aussel: “Intestinal permeability in liver cirrhosis: Relationship with severe septic complications”, Eur. J. Gastroenterol. Hepatol., Vol. 11, (1999), pp. 755–759.PubMedGoogle Scholar
  158. [158]
    S.F. Solga: “Probiotics can treat hepatic encephalopathy”, Med. Hypotheses, Vol. 61, (2003), pp. 307–313.PubMedGoogle Scholar
  159. [159]
    G. Bongaerts, R. Severijnen and H. Timmerman: “Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy”, Med. Hypotheses, Vol. 64, (2005), pp. 64–68.PubMedGoogle Scholar
  160. [160]
    M. Boca, M. Vyskocil, M. Mikulecky, L. Ebringer, E. Kolibas, H. Kratochvilova and D. Buzgova: “Complex therapy of chronic hepatic encephalopathy supplemented with a probiotic: comparison of two studies”, Cas. Lek. Cesk., Vol. 143, (2004), pp. 324–328.PubMedGoogle Scholar
  161. [161]
    Q. Liu, Z.P. Duan, D.K. Ha, S. Bengmark, J. Kurtovic and S.M. Riordan: “Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis”, Hepatology, Vol. 39, (2004), pp. 1441–1449.PubMedGoogle Scholar
  162. [162]
    J. Medina, L.I. Fernandez-Salazar, L. Garcia-Buey and R. Moreno-Otero: “Approach to the pathogenesis and treatment of nonalcoholic steatohepatosis”, Diabetes Care, Vol. 27, (2004), pp. 2057–2066.PubMedGoogle Scholar
  163. [163]
    C.S. Chang, S.S. Yang, C.H. Kao, H.Z. Yeh and G.H. Chen: “Small intestinal bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis”, Scand. J. Gastroenterol., Vol. 36, (2001), pp. 92–96.PubMedCrossRefGoogle Scholar
  164. [164]
    L. Ruiz-del-Arbol, J. Urman, J. Fernandez, M. Gonzales, M. Navasa, A. Monescillo, A. Albillos, W. Jimenez and W. Arroyo: “Systemic, renal and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis”, Hepatology, Vol. 38, (2003), pp. 1210–1218.PubMedGoogle Scholar
  165. [165]
    A. Olah, T. Belagyi, A. Issekurz, M.E. Gamal and S. Bengmark: “Randomized clinical trial of specific Lactobacillus and fibre supplement to early nutrition in patients with acute pancreatitis”, Brit. J. Surg., Vol. 89, (2002), pp. 1103–1007.PubMedGoogle Scholar
  166. [166]
    K.Y. Wang, S.N. Li, C.S. Liu, D.S. Perng, Y.C. Su, D.C. Wu, C.M. Jan, C.H. Lai, T.N. Wang and W.M Wang: “Effects of ingesting Lactobacillus-and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori”, Am. J. Clin. Nutr., Vol. 80, (2004), pp. 737–741.PubMedGoogle Scholar
  167. [167]
    M. Linsalata, F. Russo, P. Berloco, M.L. Caruso, G.D. Matteo, M.G. Cifone, C.D. Simone, E. Ierardi and A. Di Leo: “The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa”, Helicobacter, Vol. 9, (2004), pp. 165–172.PubMedGoogle Scholar
  168. [168]
    F. Cremonini, S. Di Caro, M. Covino, A. Armuzzi, M. Gabrielli, L. Santarelli, E.C. Nista, G. Cammarota, G. Gasbarrini and A. Gasbarrini: “Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel-group, triple-blind, placebo-controlled study”, Am. J. Gastroenterol., Vol. 97, (2002), pp. 2744–2749.PubMedGoogle Scholar
  169. [169]
    J.M. Hamilton-Miller: “The role of probiotics in the treatment and prevention of Helicobacter pylori infection”, Int. J. Antimicrob. Agents, Vol. 22, (2003), pp. 360–366.PubMedGoogle Scholar
  170. [170]
    R. Lodinova-Zadnikova, H. Tlaskalova and Z. Bartakova: “The antibody response in infants after colonization of the intestine with E. coli O83. Artificial colonization used as prevention against nosocomial infections”, Adv. Exp. Biol. Med., Vol. 310, (1991), pp. 329–333.Google Scholar
  171. [171]
    R. Lodinova-Zadnikova, M. Slavikova, H. Tlaskalova-Hogenova, I. Adlerberth, L.A. Hanson, A. Wold, B. Carlsson, C. Svanborg and L. Mellander: “The antibody response in breast-fed and non-breast-fed infants after artificial colonization of the intestine with Escherichia coli O83”, Pediatr. Res., Vol. 29, (1991), pp. 396–399.PubMedGoogle Scholar
  172. [172]
    R. Lodinova-Zadnikova, B. Cukrowska and H. Tlaskalova-Hogenova: “Oral administration of probiotic Escherichia coli after birth reduces frequency of allergies and repeated infections later in life (after 10 and 20 years)”, Int. Arch. Allergy Immunol., Vol. 131, (2003), pp. 209–211.PubMedGoogle Scholar
  173. [173]
    M. Kaliomäki, S. Salminen, H. Arvilommi, P. Kero, P. Koskinen and E. Isolauri: “Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial”, Lancet, Vol. 357, (2001), pp. 1076–1079.Google Scholar
  174. [174]
    M. Kaliomäki, S. Salminen, T. Poussa, H. Arvilommi and E. Isolauri: “Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial”, Lancet, Vol. 361, (2003), pp. 1869–1871.Google Scholar
  175. [175]
    V. Rosenfeldt, E. Benfeldt, S.D. Nielsen, K.F. Michaelsen, D.L. Jeppesen, N.H. Valerius and A. Paerregaard: “Effect of probiotic Lactobacillus strains in children with atopic dermatitis”, J. Allergy Clin. Immunol., Vol. 111, (2003), pp. 389–395.PubMedGoogle Scholar
  176. [176]
    M. Viljanen, E. Savilahti, T. Haahtela, K. Juntunen-Backman, R. Korpela, T. Poussa, T. Tuure and M. Kuitunen: “Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: A double-blind placebo-controlled trial”, Allergy, Vol. 60, (2005), pp. 494–500.PubMedGoogle Scholar
  177. [177]
    S. Bengmark: “Use of some pre-, pro-and synbiotics in critically ill patients”, Best. Pract. Res. Clin. Gastroenterol., Vol. 17, (2003), pp. 833–848.PubMedGoogle Scholar
  178. [178]
    P.K. Jain, C.E. McNaught, A.D. Anderson, J. MacFie and C.J. Mitchell: “Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: A randomised controlled trial”, Clin. Nutr., Vol. 23, (2004), pp. 467–475.PubMedGoogle Scholar
  179. [179]
    A.D. Anderson, C.E. McNaught, P.K. Jain and J. MacFie: “Randomised clinical trial of synbiotic therapy in elective surgical patients”, Gut, Vol. 53, (2004), pp. 241–245.PubMedGoogle Scholar
  180. [180]
    N. Rayes, D. Seehofer, T. Theruvath, R.A. Schiller, J.M. Langrehr, S. Jonas, S. Bengmark and P. Neuhaus: “Supply of pre-and probiotics reduces bacterial infection rates after liver transplantation — a randomized, double-blind trial”, Am. J. Transplant., Vol. 5, (2005), pp. 125–130.PubMedGoogle Scholar
  181. [181]
    H. Fang, T. Elina, A. Heikki and S. Seppo: “Modulation of humoral immune response through probiotic intake”, FEMS Immunol. Med. Microbiol., Vol. 29, (2000), pp. 47–52.PubMedGoogle Scholar
  182. [182]
    C. Grangette, H. Müller-Alouf, D. Goudercourt, M.C. Geoffroy, M. Turneer and A Mercenier: “Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum”, Infect. Immun., Vol. 69, (2001), pp. 1547–1553.PubMedGoogle Scholar
  183. [183]
    H. Duc le and S.M. Cutting: “Bacterial spores as heat stable vaccine vehicles”, Expert Opin. Biol. Ther., Vol. 3, (2003), pp. 1263–1270.PubMedGoogle Scholar
  184. [184]
    S. Rao, S. Hu, L. McHugh, K. Lueders, K. Henry, Q. Zhao, R.A. Fekete, S. Kar, S. Adhya and D.H. Hamer: “Toward a live microbial microbicide for HIV: Commensal bacteria secreting an HIV fusion inhibitor peptide”, Proc. Natl. Acad. Sci., Vol. 102, (2005), pp. 11993–11998.PubMedGoogle Scholar
  185. [185]
    A.M. Westendorf, F. Gunzer, S. Deppenmeier, D. Tapadar, J.K. Hunger, M.A. Schmidt, J. Buer and D. Bruder: “Intestinal immunity of Escherichia coli Nissle 1917: A safe carrier for therapeutic molecules”, FEMS Immunol. Med. Microbiol., Vol. 43, (2005), 373–384.PubMedGoogle Scholar
  186. [186]
    M.K. Salminen, S. Tynkkynen, H. Rautelin, M. Saxelin, M. Vaara, P. Ruutu, S. Sarna, V. Valtonen and A. Jarvinen: “Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland”, Clin. Infect. Dis., Vol. 35, (2002), 1155–1160.PubMedGoogle Scholar
  187. [187]
    Z. Lherm, C. Monet, B. Nougiere, B. Soulier, D. Larbi, C. De Gall, D. Caen and C. Malbrunot: “Seven cases of fungemia with Saccharomyces boulardii in critically ill patients”, Intensive Care Med., Vol. 28, (2002), pp.797–801.PubMedGoogle Scholar
  188. [188]
    A.J. Riquelme, M.A. Calvo, A.M. Guzman, M.S. Depix, P. Garcia, C. Perez, M. Arrese and J.A. Labarca: “Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients”, J. Clin. Gastroenterol., Vol. 36, (2003), pp. 41–43.PubMedGoogle Scholar
  189. [189]
    F. Lestin, A. Pertschy and D. Rimek: “Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple co-morbidities”, Dtsch. Med. Wschr., Vol. 128, (2003), pp. 2531–2533.PubMedGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Premysl Fric
    • 1
  1. 1.Department of Medicine, First Faculty of MedicineCharles University and Central Army HospitalPragueCzech Republic

Personalised recommendations